Wacker Chemie AG and CordenPharma International GmbH, together with Ludwig Maximilian University of Munich (LMU) and Humboldt University Berlin (HU Berlin), have launched a project to accelerate the development of RNA-based drugs. The aim is to develop a new generation of lipid nanoparticles (LNPs), which are an essential component of RNA-based drugs. Based on these formulations, a machine learning algorithm is to be trained that automatically identifies the ideal components for new RNA formulations – so far a particularly time-consuming and cost-intensive development step. The project, which will start on 1 April 2023, is scheduled to run for three years and is funded by the Federal Ministry for Economic Affairs and Energy with around € 1.4 million
Read More